Search results
Showing 151 to 200 of 648 results for diabetes
Promoting independence through intermediate care - a quick guide for staff delivering intermediate care services.
Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)
This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.
monitoring in adults with type 1 diabetes. Source guidance details Comes from guidance Type 1 diabetes in adults: diagnosis...
under 40: In adults aged under 40 with hypertension (with or without type 2 diabetes), what are the appropriate risk and blood pressure...
use of C-peptide in diagnosing diabetes: What is the effectiveness of C‑peptide at correcting misclassification of diabetes...
type 1 diabetes and other types of diabetes: What are the best clinical features or combination of features for...
Keep the size of your waist to less than half of your height, updated NICE draft guideline recommends
children and young people with type 1 diabetes. Source guidance details Comes from guidance Diabetes (type 1 and type 2) in...
children and young people with type 1 diabetes. Source guidance details Comes from guidance Diabetes (type 1 and type 2) in...
Continuous glucose monitoring in children and young people with type 2 diabetes: What is the effectiveness and cost effectiveness of...
Smoking: smoking status for people with long-term conditions (IND97)
This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM38
This indicator covers the proportion of adults with a diagnosis of diabetes who have a recording of myocardial infarction (MI), stroke and/or end stage kidney disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG12
This indicator covers the percentage of patients with diabetes who have a record of a dietary review by a suitably competent professional in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM28
This indicator covers the percentage of patients newly diagnosed with diabetes, on the register, in the preceding 1 April to 31 March who have a record of being referred to a structured education programme within 9 months after entry on to the diabetes register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM27
This indicator covers the percentage of patients with diabetes with moderate or severe frailty, on the register, in whom the last IFCC-HbA1c is 75 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM158
This indicator covers the percentage of patients with diabetes without moderate or severe frailty, on the register, in whom the last IFCC-HbA1c is 58 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM157
This indicator covers the percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 58 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM141
This indicator covers the percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 64 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM96.
This indicator covers the percentage of patients with diabetes who have had the following care processes performed in the preceding 12 months: BMI measurement, BP measurement, HbA1c measurement, cholesterol measurement, record of smoking status, foot examination, albumin:creatinine ratio, eGFR creatinine measurement. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM74
Diabetes: structured education within 12 months of diagnosis (IND11)
This indicator covers the proportion of adults with diabetes referred to a structured education programme within 12 months of diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG14
This indicator covers the proportion of adults with diabetes who have received all 9 basic care processes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG13
This indicator covers establishing and maintaining a register of all patients aged 17 or over with diabetes mellitus, which specifies the type of diabetes where a diagnosis has been confirmed. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM41
This indicator covers the percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 75 mmol/mol or less in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM97.
More than 250,000 people living with type 1 diabetes are set to be offered new technology to help them manage their condition and at the same time reduce the need for finger prick testing by up to 50%, following new advice from NICE.
This quality standard covers diagnosing and managing type 1 and type 2 diabetes in children and young people (under 18). It describes high-quality care in priority areas for improvement.
View quality statements for QS125Show all sections
Sections for QS125
- Quality statements
- Quality statement 1: Same-day referral and appointments
- Quality statement 2: Education and information
- Quality statement 3: Intensive insulin therapy and level 3 carbohydrate-counting education for type 1 diabetes
- Quality statement 4: Continuous glucose monitoring in type 1 diabetes
- Quality statement 5: Blood ketone monitoring in type 1 diabetes
- Quality statement 6: Access to mental health professionals with an understanding of type 1 or type 2 diabetes
- Update information
This indicator covers the proportion of eligible people with diabetes who are offered an appointment for diabetic eye screening. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG88
Diabetes: annual psychological assessment (children) (IND57)
This indicator covers the proportion of children and young people with diabetes who have received a psychological assessment in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG76
This indicator covers the proportion of young people with diabetes age 12 to 18 years who have had their smoking status recorded in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG74
This indicator covers admission rates due to lower limb amputations in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG65
This indicator covers admission rates due to heart failure in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG61
This indicator covers admission rates due to diabetic ketoacidosis in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG64
Diabetes: admission rates (renal replacement therapy) (IND45)
This indicator covers admission rates for renal replacement therapy in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG63
This indicator covers admission rates due to myocardial infarction in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG60
This indicator covers admission rates due to stroke in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG62
This indicator covers admission rates due to angina in people with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG59
This indicator covers admission rates for people with diabetes due to complications associated with diabetes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG58
clinical and cost effectiveness of SGLT2 inhibitors in adults with type 2 diabetes and chronic kidney disease, stratified across...
clinical and cost effectiveness of SGLT2 inhibitors in adults with type 2 diabetes, chronic kidney disease and a urine ACR of less than...
aids)• comorbidities (chronic obstructive pulmonary disease, hypertension, diabetes, coronary heart disease, chronic kidney disease,...
Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)
Evidence-based recommendations on empagliflozin (Jardiance) for treating chronic heart failure with reduced ejection fraction in adults.
Evidence-based recommendations on dapagliflozin (Forxiga) for chronic kidney disease in adults.
Lumella point-of-care test for assessing pre-eclampsia risk (MIB287)
NICE has developed a medtech innovation briefing (MIB) on Lumella point-of-care test for assessing pre-eclampsia risk .
This indicator covers the proportion of eligible people with diabetes who are excluded from diabetic eye screening as they have opted out or are classed as medically unfit. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG90
1 Type 2 diabetes: agreeing my blood glucose (HbA1c) target Patient decision aid c NICE 2022. All rights reserved. Subject to Notice of...
NICE has developed a medtech innovation briefing (MIB) on d-Nav insulin management app for type 2 diabetes .
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)
Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage 3 melanoma in adults.
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active psoriatic arthritis in adults.
drug treatments to control blood glucose levels: In adults with type 2 diabetes, what are the effects of stopping and/or switching drug...
outcomes associated with blood glucose lowering agents: In adults with type 2 diabetes, what are the long‑term effects of blood glucose...
treatment combinations to control blood glucose levels: In adults with type 2 diabetes, what treatment combinations (for example,...